FC
DRNA

FORA Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

FORA Capital’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,207
Closed -$132K – 1099
2020
Q2 		$132K Buy
+5,207
New +$112K 0.05% 431
2020
Q1 		– Sell
-9,024
Closed -$199K – 1440
2019
Q4 		$199K Buy
+9,024
New +$182K 0.02% 618

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

FORA Capital's DRNA Position: Q3 2020 in Review

FORA Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 5,207 shares — an estimated $132K sold.

FORA Capital first reported a position in DRNA in Q4 2019 and held it in 2 quarters. The position peaked at $199K in Q4 2019. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

  • FORA Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • FORA Capital sold 5,207 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $132K.
  • FORA Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • FORA Capital's Dicerna Pharmaceuticals, Inc. position peaked at $199K in Q4 2019.
  • 172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.